{"name":"Aldeyra Therapeutics","slug":"aldeyra","ticker":"ALDX","exchange":"NASDAQ","domain":"aldeyra.com","description":"Aldeyra Therapeutics is a biotechnology company focused on developing innovative treatments for ophthalmic diseases and inflammation. The company's pipeline includes several promising candidates, including reproxalap for dry eye disease and ADX-2191 for retinal diseases. Aldeyra Therapeutics is a relatively small company with a limited market presence, but its research and development efforts have generated significant interest among investors. The company's top drugs are reproxalap and ADX-2191.","hq":"Lexington, MA","founded":2015,"employees":"75","ceo":"Todd C. Brady","sector":"Ophthalmology / Inflammation","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":123000000,"metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":25662855,"netIncome":-33846661,"cash":72059317,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2034-06-01","label":"reproxalap patent cliff ($0.0B at risk)","drug":"reproxalap","type":"patent_expiry","sentiment":"negative"},{"date":"2035-06-01","label":"ADX-2191 patent cliff ($0.0B at risk)","drug":"ADX-2191","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Ophthalmology","slug":"ophthalmology","revenue":0,"percentOfTotal":0,"drugCount":7,"colorKey":"oncology","drugs":[{"name":"ICM ADX-2191 injection","genericName":"ICM ADX-2191 injection","slug":"icm-adx-2191-injection","indication":"Dry eye disease","status":"phase_3"},{"name":"Active topical NS2 1% dermatologic cream","genericName":"Active topical NS2 1% dermatologic cream","slug":"active-topical-ns2-1-dermatologic-cream","indication":"Treatment of dry eye disease","status":"phase_2"},{"name":"Monthly ADX-2191 injection","genericName":"Monthly ADX-2191 injection","slug":"monthly-adx-2191-injection","indication":"Dry eye disease","status":"phase_3"},{"name":"Vehicle Ophthalmic Solution QID","genericName":"Vehicle Ophthalmic Solution QID","slug":"vehicle-ophthalmic-solution-qid","indication":"Used as a control in clinical trials for ophthalmic conditions","status":"phase_3"},{"name":"Vehicle Ophthalmic Solution QID to BID","genericName":"Vehicle Ophthalmic Solution QID to BID","slug":"vehicle-ophthalmic-solution-qid-to-bid","indication":"Ophthalmic indication (specific indication not specified in available information)","status":"phase_3"},{"name":"Vehicle Opthalmic Solution","genericName":"Vehicle Opthalmic Solution","slug":"vehicle-opthalmic-solution","indication":"Treatment of dry eye disease","status":"phase_3"},{"name":"Vehicle of ADX-102 Ophthalmic Drops","genericName":"Vehicle of ADX-102 Ophthalmic Drops","slug":"vehicle-of-adx-102-ophthalmic-drops","indication":"Dry eye disease","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"ADX-2191","genericName":"ADX-2191","slug":"adx-2191","indication":"Proliferative vitreoretinopathy (PVR)","status":"phase_2"},{"name":"ADX-629","genericName":"ADX-629","slug":"adx-629","indication":"Other","status":"phase_2"}]},{"name":"Dermatology","slug":"dermatology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Vehicle of ADX-102 Topical Dermal Cream","genericName":"Vehicle of ADX-102 Topical Dermal Cream","slug":"vehicle-of-adx-102-topical-dermal-cream","indication":"Vernal keratoconjunctivitis","status":"phase_3"}]}],"pipeline":[{"name":"ICM ADX-2191 injection","genericName":"ICM ADX-2191 injection","slug":"icm-adx-2191-injection","phase":"phase_3","mechanism":"ADX-2191 is a reactive aldehyde species that inhibits aldehyde dehydrogenase (ALDH) to modulate immune and inflammatory responses.","indications":["Dry eye disease","Ocular surface disease"],"catalyst":""},{"name":"ADX-2191","genericName":"ADX-2191","slug":"adx-2191","phase":"phase_2","mechanism":"ADX-2191 is designed to inhibit the activity of Rho-associated protein kinase (ROCK), which is involved in various cellular processes including inflammation and cell proliferation.","indications":["Proliferative vitreoretinopathy (PVR)"],"catalyst":""},{"name":"ADX-629","genericName":"ADX-629","slug":"adx-629","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Active topical NS2 1% dermatologic cream","genericName":"Active topical NS2 1% dermatologic cream","slug":"active-topical-ns2-1-dermatologic-cream","phase":"phase_2","mechanism":"Active topical NS2 1% dermatologic cream works by targeting the underlying cause of inflammation in the skin.","indications":["Treatment of dry eye disease"],"catalyst":""},{"name":"Monthly ADX-2191 injection","genericName":"Monthly ADX-2191 injection","slug":"monthly-adx-2191-injection","phase":"phase_3","mechanism":"ADX-2191 is a reactive aldehyde species (RAS) scavenger that binds and neutralizes pathogenic aldehydes implicated in ocular surface inflammation and disease.","indications":["Dry eye disease","Ocular surface inflammation"],"catalyst":""},{"name":"Vehicle Ophthalmic Solution QID","genericName":"Vehicle Ophthalmic Solution QID","slug":"vehicle-ophthalmic-solution-qid","phase":"phase_3","mechanism":"Vehicle Ophthalmic Solution QID is a carrier solution used in clinical trials to deliver active drugs to the eye, without having a direct therapeutic effect itself.","indications":["Used as a control in clinical trials for ophthalmic conditions"],"catalyst":""},{"name":"Vehicle Ophthalmic Solution QID to BID","genericName":"Vehicle Ophthalmic Solution QID to BID","slug":"vehicle-ophthalmic-solution-qid-to-bid","phase":"phase_3","mechanism":"A vehicle ophthalmic solution formulation designed to be administered topically to the eye at varying frequencies (four times daily reduced to twice daily).","indications":["Ophthalmic indication (specific indication not specified in available information)"],"catalyst":""},{"name":"Vehicle Opthalmic Solution","genericName":"Vehicle Opthalmic Solution","slug":"vehicle-opthalmic-solution","phase":"phase_3","mechanism":"Vehicle Ophthalmic Solution is a non-medicated solution used to flush out the eye.","indications":["Treatment of dry eye disease"],"catalyst":""},{"name":"Vehicle of ADX-102 Ophthalmic Drops","genericName":"Vehicle of ADX-102 Ophthalmic Drops","slug":"vehicle-of-adx-102-ophthalmic-drops","phase":"phase_3","mechanism":"This is a vehicle formulation (inactive carrier system) for ADX-102, designed to deliver the active pharmaceutical ingredient to the ocular surface.","indications":["Dry eye disease","Allergic conjunctivitis"],"catalyst":""},{"name":"Vehicle of ADX-102 Topical Dermal Cream","genericName":"Vehicle of ADX-102 Topical Dermal Cream","slug":"vehicle-of-adx-102-topical-dermal-cream","phase":"phase_3","mechanism":"ADX-102 is a topical dermal cream that targets the complement pathway to reduce inflammation.","indications":["Vernal keratoconjunctivitis","Atopic keratoconjunctivitis"],"catalyst":""}],"recentEvents":[{"date":"2023-02-28","type":"earnings","headline":"Aldeyra Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results","summary":"Aldeyra Therapeutics reported its financial results for the fourth quarter and full year 2022, with a net loss of $24.4 million and $93.8 million, respectively.","drugName":"","sentiment":"neutral"},{"date":"2022-11-07","type":"deal","headline":"Aldeyra Therapeutics Announces Collaboration with the National Eye Institute","summary":"Aldeyra Therapeutics announced a collaboration with the National Eye Institute to develop new treatments for dry eye disease.","drugName":"","sentiment":"positive"},{"date":"2022-08-09","type":"trial","headline":"Aldeyra Therapeutics Announces Positive Topline Results from Phase 3 Trial of Reproxalap","summary":"Aldeyra Therapeutics announced positive topline results from a Phase 3 trial of reproxalap for dry eye disease.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMitAJBVV95cUxOUkZ6RmoyY3k1dmJfOUZQMHdjWmRlUDhoSEFMVmplZkgyT1ZSaUZ2czljWl9BQTJuY2FDZ3FXSUJhWEp2Q2t4MjNrYl8wRGZhWmdRUFNtWlR5cWxZM2c3V2QweWNJM0tUTzNlRXc3c1FJWnVoMVdrbXBsZnhFeF9Bd3ZKY1NPREcwbGtUbnppY3QwelN6TFZoNkNZWEt0WENZby1KdC16a2twSE1VdWFvZm9oaUN5Q1JuZzBMY256NUtDdDVZU21PZ0pXdENqRW5UbXpwc2U4QjE4TTBnTUZVS2lQOVRYbDE5dlNFZVNReFpWalhGYnhBWjBtODA2RzRTZWxWc1d2R21NN2c5bG1PMmF5YVkwUEtXeFF0MzNPbktfYkxxTHJteW1PaENjXzZmeUlwRA?oc=5","date":"2026-04-06","type":"pipeline","source":"globenewswire.com","summary":"ADLX Class Action Notice: Robbins LLP Reminds Investors of - globenewswire.com","headline":"ADLX Class Action Notice: Robbins LLP Reminds Investors of","sentiment":"neutral"},{"date":"2026-04-01","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxNTXZBZmRERGlQWVBSTmU5LUZnSkRIUW5hZURjZnBrYjlvS2g2dmxIRnpxZjVSY2lMRlVka2k3Q2pLdW1FblllNDhsRWlfbVBLVHBHNnNkYkE3Z2pzQlNDT2NWMkZlX2NZVU1lbk1IdTVhSWk5MFBqamhIUEtxaUtLcl95YnBGTG9WUjZhaUVTUGhfMm5BMlZGQ1JhSFFDZ0FabUF4Tk9BWWhjd3NXU0pBUDFCZi0?oc=5","date":"2026-03-19","type":"pipeline","source":"Benzinga","summary":"12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga","headline":"12 Health Care Stocks Moving In Thursday's Intraday Session","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6AFBVV95cUxOZExoaDlwZHloVm16cXBqazVNT09mZlNUY2dGQlR3OUFSbkJFaEgyUVF0dXpPTUhhdHNicmFETEZyOHk0czRVRGswMENIamx5WUVwVkpsX3ptNzlKUW9vR1lfNUFZZTlzLVFBQ01SekdLTHRJWHVxcFJZeW9FSV9jeVYwWUxwbUlyeC1ELXIxYkwzbFZWNXM3cnc4Qm9NVS1FWDNJZVQzbm55MTNYeGVMVS1QclVIVGpwaWhTYmwwaWhmS2xTVERIZE1XRy1oMkxVVmNpMFJnS19HWlM3VDA3aGg3Snlqdnpf0gHuAUFVX3lxTFBLYnl6U0Y2cU5FQzAwQnJoYkp2YlpoNHJQV3JGOEZkcFJmNVowR3ZTZ3lJYzZGVWJ2N0tYMGNqTnpEZk9qbWNVN25QbndZWkpVRERZYXl2YTBISmIxaFUzNGpBN3d5a21XdXFhR3hLTzg0LWF3cHJsU2Z5ejItTGdBQVBUaTN2V09hOFVFNjRmNDNyYXhFUkpqNEM5UkdBTDQwT3JNU3NqeWFDeVg5TU5jQS02QUdsRFVWWDdhaGVyTjk1Q3V5T1hRcHU1dEQ0THd1OUVzZkh2ZXhLOTFCVlAwZkFiallLZEI1OFdLUWc?oc=5","date":"2026-03-18","type":"regulatory","source":"simplywall.st","summary":"Aldeyra Therapeutics (ALDX) Is Down 75.2% After FDA Rebuffs Dry Eye Drug Efficacy Data - Has The Bull Case Changed? - simplywall.st","headline":"Aldeyra Therapeutics (ALDX) Is Down 75.2% After FDA Rebuffs Dry Eye Drug Efficacy Data - Has The Bull Case Changed?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxPX25sZDBkUlBnV2dRMU95V2V5cVlFU2VocnR1ZWU0SUsxLVA5YzYxaWRfWkZ3TjVSUUJuc0ZCaVczbU5LY3JtOVl3UVpjbnpSTklNRjh6WmdFbzFpVF81TVNMVnA0N2ZJVTBKNGhXVVk0c0dMYTkyUUVvbFRtbURVeTZ1V2JiRUFWRkotUnNUbUI0NUxzdnR4TC1CYzJFWFJSUUJ1dXRmN2dmUQ?oc=5","date":"2026-03-18","type":"regulatory","source":"The Pharma Letter","summary":"Aldeyra shares plunge after third FDA rejection for reproxalap - The Pharma Letter","headline":"Aldeyra shares plunge after third FDA rejection for reproxalap","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxPZHVYaHRsUDdOdVVHcXd2V1B4b3oxN2hVY3NxbEd5X3pIYmRqazE0TWJYOHd1bFBLN1hXaW11VEJ0Tm5ZYVM5Ylhxb2FzeFh1RmFxMTBJT20wYkVGX3RocmEyVS02Z3BCQkNfQ09kbVlCZTZ0WlBQSDFlVzAxNDJjRFFfY25oRkNHSC1FLUpNMXFjNFYzR1NvYU0zdTJ6V3F3c1NJeWVMdm9PSHFCYU9PWTBKel9Id1hLd1Y4d3JSWQ?oc=5","date":"2026-03-17","type":"regulatory","source":"Reuters","summary":"US FDA declines to approve Aldeyra's eye disorder drug, shares slump - Reuters","headline":"US FDA declines to approve Aldeyra's eye disorder drug, shares slump","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxPc3BSNHdVZmRlVWw0NjFmUTBEWS02VGVFUzhVLXlaai1tZEw0dnFxYlo4c0xkWTJnYmN2bk5YS2wzX09aTFdnY2ZtR3J6MTZGc3VRT1V6cld1SUMxOFBvanRyczU2NW1scFllZWRWUGVQbEozUHZHNDNSMmdGbkFVTzZuY1QybUZsRnFsYllXc0ZWTjVpcEx0Qi13?oc=5","date":"2026-03-17","type":"regulatory","source":"PharmaLive","summary":"US FDA declines to approve Aldeyra’s eye disorder drug, shares slump - PharmaLive","headline":"US FDA declines to approve Aldeyra’s eye disorder drug, shares slump","sentiment":"positive"},{"date":"2026-03-17","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-02-27","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2025-12-31","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE1qX2xyWklHeG9keGNHYWh6LUd4aXhvTThnUm83aEJUQUlHZ0c1WHVqc05GV005YUNpcDQwcm1TOHB6QWROYjZRVUxxM01zYzcyMXAw?oc=5","date":"2025-12-16","type":"regulatory","source":"firstwordpharma.com","summary":"FDA pushes back decision for Aldeyra's dry-eye therapy - firstwordpharma.com","headline":"FDA pushes back decision for Aldeyra's dry-eye therapy","sentiment":"neutral"},{"date":"2025-12-16","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-11-27","type":"pipeline","source":"simplywall.st","summary":"Does Aldeyra Therapeutics (NASDAQ:ALDX) Have A Healthy Balance Sheet? - simplywall.st","headline":"Does Aldeyra Therapeutics (NASDAQ:ALDX) Have A Healthy Balance Sheet?","sentiment":"neutral"},{"date":"2025-11-13","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-11-05","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"}],"patents":[{"drugName":"reproxalap","drugSlug":"reproxalap","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":0},{"drugName":"ADX-2191","drugSlug":"adx-2191","patentNumber":"","type":"Patent Cliff","expiryDate":"2035-06-01","territory":"US","annualRevenue":0}],"drugCount":10,"phaseCounts":{"phase_3":7,"phase_2":3},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Regeneron Pharmaceuticals","Allergan","Novartis"],"therapeuticFocus":["Ophthalmology","Inflammation"],"financials":{"source":"sec_edgar+yahoo","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":25662855,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-33846661,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":72059317,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}